Dave Rosa, President and CEO discusses NeuroOne, a medical technology company focused on the development and commercialization of minimally invasive and high-definition/high-precision solutions for epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries. These solutions include electrodes that have the potential to reduce the number of hospitalizations, surgical procedures, and cost while improving patient outcomes due to their potential for offering combination diagnostic and therapeutic functions such as EEG recording and tissue ablation, and/or chronic stimulation. A combination recording and RF ablation technology are currently under development. In addition, NeuroOne recently announced the initial results of testing its electrodes for long-term recording and stimulation. The Company is also investigating the potential application of its technology for artificial intelligence and machine learning.
Dave Rosa, President & Chief Executive Officer
Mr. Rosa is an entrepreneur with three decades of experience in the medical device industry spanning a variety of technologies and products. In addition to CEO roles with early-stage medical device companies, Mr. Rosa’s background also includes senior roles with C.R. Bard Inc., Boston Scientific Inc., and St. Jude Medical, where his responsibilities included marketing, product development and business development. He has been named as an inventor on multiple medical device patents, serves on seven corporate boards, and has raised $200M in the capital markets. Mr. Rosa holds an MBA from Duquesne University and a BS in Commerce and Engineering from Drexel University.